Gujarat Inject (Kerala) share news, announcements and annual reports
BSE: 524238Pharmaceuticals & BiotechnologySmall Cap
Gujarat Inject (Kerala) Ltd. · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Oct 1992
Last close ₹11.16down ₹0.06 (0.53%)
Share price at the BSE close on 30 Oct 2026. Previous close ₹11.22.
30 Oct: open ₹11.29, high ₹11.54, low ₹10.77
52-week range of traded prices to 30 Oct 2026
₹2.06Low, 30 Oct 2025₹14.30High, 9 Jul 2026
- Next results date: the board meets on 5 Nov 2026 to consider: quarterly results. Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹163 Cr2,790th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 54.64
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 13.82
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 32.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,44,603
Gujarat Inject (Kerala) share news and announcements
407 announcements, routine notices left out, newest first. Page 2 of 9.
Feb 2026
14 Feb · Results
11 Feb · Board meeting
Meeting on 14 Feb 2026: quarterly results
Dec 2025
Nov 2025
13 Nov · Results
11 Nov · Board meeting
Meeting on 13 Nov 2025: quarterly results
Oct 2025
Sep 2025
8 Sep · Board meeting
Aug 2025
14 Aug · Results
11 Aug · Board meeting
Meeting on 14 Aug 2025: quarterly results
Jul 2025
25 Jul · Board meeting
7 Jul · Management
7 Jul · Board meeting
Jun 2025
May 2025
20 May · Results
16 May · Board meeting
Meeting on 20 May 2025: audited results
Apr 2025
Mar 2025
12 Mar · Meeting
Feb 2025
14 Feb · Board meeting
Meeting on 18 Feb 2025: stock split1 Feb · Board meeting
Meeting on 5 Feb 2025: stock split
Jan 2025
20 Jan · Board meeting
Meeting on 23 Jan 2025: quarterly results
Oct 2024
7 Oct · Board meeting
Meeting on 22 Oct 2024: quarterly results
Sep 2024
5 Sep · Meeting
Aug 2024